ALI & Pulmonary HA Deposition After SAH

March 16, 2026 updated by: Xintong Ge, Tianjin Medical University

Relationship Between Acute Lung Injury and Pulmonary Hyaluronic Acid Deposition After Subarachnoid Hemorrhage

Acute lung injury is a common complication of subarachnoid hematoma (SAH), and a significant risk factor for death in patients with SAH. Unlike neurogenic pulmonary edema and pneumonia following brain injury, the clinical causes of pulmonary injury after SAH are not intracranial hypertension or pulmonary infection. Its occurrence is influenced by the release of catecholamines, the regulatory function of the hypothalamic-pituitary-adrenal (HPA) axis and systemic inflammatory response, but the specific mechanisms are still unclear. Therefore, delving into the pathological mechanisms of SAH-induced lung injury and developing therapeutic strategies based on the findings is of great importance to improve the prognosis of patients.

Abnormal accumulation of hyaluronic acid in the lungs has been reported to be closely related to the pathological progression of various pulmonary injury diseases, such as chest trauma, pulmonary infection and chronic obstructive pulmonary disease. From this, the present research is aimed to explore the levels and dynamic changes of hyaluronic acid in the bronchoalveolar lavage fluid and blood of patients with acute lung injury following SAH, and to analyze its correlation with the prognosis of pulmonary complications, thereby providing assistance for the clinical diagnosis and treatment of SAH.

Study Overview

Status

Recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

24

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Xintong Dr. Ge
  • Phone Number: 86-13662055012
  • Email: xge@tmu.edu.cn

Study Locations

  • China
      • Tianjin, China, 300052
        • Recruiting
        • Tianjin Medical University General Hospital
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Estimated by statistical analysis, a total of 24 subjects were included from patients admitted to the neurosurgical intensive care unit of Tianjin Medical University General Hospital and the intensive care unit of Tianjin Huanhu Hospital due to aneurysmal SAH.

Description

Inclusion Criteria:

  • Age between 18 and 80 years old with independent behavior ability or authorized legal representative.
  • A documented diagnosis of SAH within 5 days.
  • A Hunt-Hess scale of Ⅳ or Ⅴ.
  • Absence of clinical and etiological evidence of pulmonary infection.

Exclusion Criteria:

  • Pregnant or lactating women.
  • Present history of traumatic brain injury or intracranial hemorrhage.
  • Past history of neurological disorders, lung infection within the past six months, cancer, chronic cardiopulmonary diseases, hematological diseases or renal failure.
  • Have participated in clinical trials in the past 4 weeks.
  • The investigator considers that not appropriate for inclusion.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Subarachnoid Hemorrhage (SAH)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Hyaluronic acid level in bronchoalveolar lavage fluid after SAH
Time Frame: During the acute phase (1-5 days post-onset) and the chronic phase (10-14 days post-onset) of patients with SAH
Hyaluronic acid level (ng/ml) in bronchoalveolar lavage fluid at the acute phase (1-5 days post-onset) and the chronic phase (10-14 days post-onset) of patients with SAH
During the acute phase (1-5 days post-onset) and the chronic phase (10-14 days post-onset) of patients with SAH
Inflammatory cytokines levels in bronchoalveolar lavage fluid after SAH
Time Frame: During the acute phase (1-5 days post-onset) and the chronic phase (10-14 days post-onset) of patients with SAH
Inflammatory cytokines (IL-1β, TNF-α and IL-10) levels (pg/ml) in bronchoalveolar lavage fluid at the acute phase (1-5 days post-onset) and the chronic phase (10-14 days post-onset) of patients with SAH
During the acute phase (1-5 days post-onset) and the chronic phase (10-14 days post-onset) of patients with SAH

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Serum hyaluronic acid level after SAH
Time Frame: During the acute phase (1-5 days post-onset) and the chronic phase (10-14 days post-onset) of patients with SAH
Serum hyaluronic acid level (ng/ml) at the acute phase (1-5 days post-onset) and the chronic phase (10-14 days post-onset) of patients with SAH
During the acute phase (1-5 days post-onset) and the chronic phase (10-14 days post-onset) of patients with SAH
Serum inflammatory cytokines levels after SAH
Time Frame: During the acute phase (1-5 days post-onset) and the chronic phase (10-14 days post-onset) of patients with SAH
Serum inflammatory cytokines (IL-1β, TNF-α and IL-10) levels (pg/ml) at the acute phase (1-5 days post-onset) and the chronic phase (10-14 days post-onset) of patients with SAH
During the acute phase (1-5 days post-onset) and the chronic phase (10-14 days post-onset) of patients with SAH

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Tianjin Medical University

Investigators

  • Study Chair: Xintong Ge, Tianjin Medical University General Hospital
  • Principal Investigator: Yadan Li, Tianjin Huanhu Hospital
  • Principal Investigator: Ye Tian, Tianjin Medical University General Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 1, 2024

Primary Completion (Estimated)

September 30, 2026

Study Completion (Estimated)

September 30, 2026

Study Registration Dates

First Submitted

September 29, 2024

First Submitted That Met QC Criteria

October 3, 2024

First Posted (Actual)

October 8, 2024

Study Record Updates

Last Update Posted (Actual)

March 18, 2026

Last Update Submitted That Met QC Criteria

March 16, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • IRB2024-YS-425-01

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Subarachnoid Haemorrhage (SAH)

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Benin

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe